Relmada Therapeutics Insider Bought Shares Worth $395,115, According to a Recent SEC Filing-February 2024-www.financetom.com

Relmada Therapeutics Insider Bought Shares Worth $395,115, According to a Recent SEC Filing

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Relmada Therapeutics Insider Bought Shares Worth $395,115, According to a Recent SEC Filing

Sep 12, 2024 12:12 AM

05:52 PM EDT, 09/11/2024 (MT Newswires) -- Sergio Traversa, Director, Chief Executive Officer, on September 09, 2024, executed a purchase for 140,000 shares in Relmada Therapeutics ( RLMD ) for $395,115. Following the Form 4 filing with the SEC, Traversa has control over a total of 384,024 shares of the company, with 384,024 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1553643/000121390024077795/xslF345X05/ownership.xml

Previous page： Market Chatter: Papa John's International Nearing Private Takeover Deal With TriArtisan-Led Group for $65 per Share Next page： Lyell Immunopharma Acquires Global Rights to CAR T-Cell Product Candidate for Colorectal Cancer

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Market Chatter: Papa John's International Nearing Private Takeover Deal With TriArtisan-Led Group for $65 per Share

Nov 10, 2025

11:09 AM EST, 11/10/2025 (MT Newswires) -- Papa John's International (PZZA) is closing in on a deal to be acquired and taken private by a consortium led by TriArtisan Capital Advisors for $65 per share, ABC Money reported Monday, citing individuals familiar with the negotiations. The offer values the restaurant chain at $2.7 billion, according to the report. Papa John's...

Lyell Immunopharma Acquires Global Rights to CAR T-Cell Product Candidate for Colorectal Cancer

Nov 10, 2025

11:13 AM EST, 11/10/2025 (MT Newswires) -- Lyell Immunopharma ( LYEL ) said Monday it acquired exclusive global rights to LYL273, a CAR T-cell product candidate for metastatic colorectal cancer, from Innovative Cellular Therapeutics. The deal includes an upfront payment of $40 million, 1.9 million Lyell shares, and up to $820 million in milestone payments, Lyell said. LYL273 showed a...

Atai Beckley Reports Positive Phase 2b Extension Data for Depression Treatment

Nov 10, 2025

11:08 AM EST, 11/10/2025 (MT Newswires) -- Atai Beckley ( ATAI ) said Monday its open-label extension of a phase 2b trial showed that an additional 12 milligram dose of BPL-003 nasal spray delivered rapid and sustained antidepressant effects for up to eight weeks. The company said 63% of patients met response criteria and 48% remission criteria at week 8...

Mayfair Gold Advances Fenn-Gib Project, Pre-Feasibility Study on Track for 2025 Completion

Nov 10, 2025

11:12 AM EST, 11/10/2025 (MT Newswires) -- Mayfair Gold ( MFGCF ) was at last look up 6.1% on Monday after it provided an update on the 2025 Mineral Resource Drilling Program, Geotechnical Site Investigations for the tailing storage facility and a progress update on the Pre-Feasibility Study (PFS) work. The company said that the Pre-Feasibility Study is on track...